TAD 600 Mg/4 ML Solution for Injection
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TAD 600 Mg/4 ML Solution for Injection, covering 2024-11-27 to 2024-11-27. Get the full timeline:
Most recent: Clinical Trial Update: Study of Intravenous TAD® 600 Mg/4 ML Solution for Injection to Evaluate Efficacy and Safety in Preventing Myocardial Injury in Patients with Pneumonia. [Phase 3]